TY - JOUR T1 - <em>De novo FZR1</em> loss-of-function variants cause developmental and epileptic encephalopathies including Myoclonic Atonic Epilepsy JF - medRxiv DO - 10.1101/2021.06.12.21256778 SP - 2021.06.12.21256778 AU - Sathiya N. Manivannan AU - Jolien Roovers AU - Noor Smal AU - Candace T. Myers AU - Dilsad Turkdogan AU - Filip Roelens AU - Oguz Kanca AU - Hyung-Lok Chung AU - Tasja Scholz AU - Katharina Hermann AU - Tatjana Bierhals AU - S. Hande Caglayan AU - Hannah Stamberger AU - Heather Mefford AU - Peter de Jonghe AU - Shinya Yamamoto AU - Sarah Weckhuysen AU - Hugo J. Bellen Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/20/2021.06.12.21256778.abstract N2 - FZR1, which encodes the Cdh1 subunit of the Anaphase Promoting Complex, plays an important role in neurodevelopment by regulating cell cycle and by its multiple post-mitotic functions in neurons. In this study, evaluation of 250 unrelated patients with developmental epileptic encephalopathies (DEE) and a connection on GeneMatcher led to the identification of three de novo missense variants in FZR1. Two variants led to the same amino acid change. All individuals had a DEE with childhood onset generalized epilepsy, intellectual disability, mild ataxia and normal head circumference. Two individuals were diagnosed with the DEE subtype Myoclonic Atonic Epilepsy (MAE). We provide gene burden testing using two independent statistical tests to support FZR1 association with DEE. Further, we provide functional evidence that the missense variants are loss-of-function (LOF) alleles using Drosophila neurodevelopment assays. Using three fly mutant alleles of the Drosophila homolog fzr and overexpression studies, we show that patient variants do not support proper neurodevelopment. With the recent report of a patient with neonatal-onset DEE with microcephaly who also carries a de novo FZR1 missense variant, our study consolidates the relationship between FZR1 and DEE, and expands the associated phenotype. We conclude that heterozygous LOF of FZR1 leads to DEE associated with a spectrum of neonatal to childhood onset seizure types, developmental delay and mild ataxia. Microcephaly can be present but is not an essential feature of FZR1-encephalopathy. In summary, our approach of targeted sequencing using novel gene candidates and functional testing in Drosophila will help solve undiagnosed MAE/DEE cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN.S. is supported by the UA-Bijzonder Onderzoeksfonds (BOF)-DOCPRO4 (FFB180186). S.Y. is supported by the following grants from the National Institutes of Health (U54NS093793, R01DC014932, R24OD022005) and through funds provided by the Nancy Chang Ph.D., Award for Research Excellence, Baylor College of Medicine, and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital. S.W. is supported by the Fonds Wetenschappelijk onderzoek (FWO 1861419N). H.M. is supported by NIH (R01 NS069605). Drosophila stocks were obtained from the Bloomington Stock Center (NIH P40OD018537) at Indiana University. Monoclonal antibodies were obtained from the Developmental Studies Hybridoma Bank, created by the NICHD, and maintained at The University of Iowa. H.J.B. is an Investigator of the Howard Hughes Medical Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethical Committee of the University of Antwerp, Belgium gave ethical approval for the study. Parents of each patient signed an informed consent form for participation in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data and supporting information are contained within the manuscript and supporting data files. https://gnomad.broadinstitute.org/ https://denovolyzer.org/ https://www.ensembl.org/info/docs/tools/vep/index.html http://www.omim.org/. https://www.rcsb.org/ ER -